Abstract: The invention provides a method of making a chewing gum composition containing a water soluble bulk portion, a water insoluble chewing gum base portion, a flavoring agent, and bismuth-containing compounds. The invention provides a method of making a bismuth-containing gum which when chewed multiple times per day, over the period of two weeks, is effective in reducing peptic ulcers by eradicating H. pylori. The chewing gum is also effective in eliminating forms of halitosis. The chewing gum does not have undesirable side effects, such as unpleasant taste and poor chewing characteristics.

Abstract: A material for the enhancement of blood coagulation. The material comprises calcium cations, an inorganic oxide, a clay, an inorganic oxide in combination with calcium cations, a zeolite in combination with calcium cations, a zeolite in combination with an inorganic oxide and combinations thereof. The material when combined with blood reduces the coagulation time of the blood. Also, a method for using the material to promote blood coagulation.

Abstract: Topical oral dosage forms containing bismuth compounds are described, which are useful for treating H. pylori and other bacterial infections that cause gastrointestinal disorders and halitosis, as well as for treating ocular and dermal wounds. Methods of employing topical oral dosage forms for treating bacterial infections that cause gastrointestinal disorders and halitosis, and for treating ocular and dermal wounds, are also described.

Abstract: The present invention relates to compositions comprising a combination of one or more antiseptic and an antibiotic. It is based, at least in part, on the discovery that such combinations tend to deter the formation of antibiotic-resistant organisms. In preferred, nonlimiting embodiments of the invention, the antibiotic is minocycline and the antiseptic is a chlorhexidine compound, triclosan, or benzalkonium chloride, and in particular embodiments, a silver salt or a bismuth salt is added. Examples of specific, nonlimiting embodiments of the invention include combinations of (i) minocycline, triclosan, and a bismuth salt; (ii) minocycline, a chlorhexidine compound, and a bismuth salt; and (iii) minocycline, benzalkonium chloride, and a bismuth salt. The present invention further provides for articles, such as, but not limited to, medical articles, which have been treated with or which otherwise comprise a combination of antiseptic and antibiotic.

Abstract: The invention relates to a method and composition for destroying or inhibiting proliferation of microbes using oxidative fluorinator compounds. Fluoride salts that do not dissociate completely in aqueous solutions, such as tri- or tetravalent transition metal fluorides, inert gas fluorides, or tri- or tetravalent rare earth fluorides, are effective antimicrobial agents even at levels up to about 20 ppm, when used alone or in conjunction with a strong oxidizer.

Abstract: The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.

Abstract: The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4.

Abstract: Nail enamel compositions of the present invention for coating natural or synthetic human nails broadly include the ingredients of one or more film forming components, preferably nitrocellulose having a molecular weight greater than 56,000, one or more solvents and bismuth oxychloride.

Abstract: The present invention relates to an orally administered sleep inducing antacid composition comprising from about 100 mg to about 2000 mg of at least one antacid, and about 300 mg to about 1000 mg of at least one sleep inducing compound wherein the amount of sleep inducing compound is based on a concentrated extract containing not less than 0.5% of the essential oil of the respective sleep inducing compound. The advantage of the sleep inducing antacid compositions are that they promote drowsiness and provide relief from excess gastrointestinal acidity.

Abstract: The invention provides methods for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with Helicobacter pylori in a patient requiring said treatment and/or prevention, which comprise administering to the patient a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent. The invention also provides pharmaceutical compositions for use in the methods of the invention.

Abstract: The present invention provides methods for preventing, treating, and/or managing one or more cancerous conditions in a patient, such as a human. A multivalent metal oxide, such as Ag(I,III), Cu(I,III), Pr(III,IV), and Bi(III,V) oxides or a pharmaceutically acceptable derivative thereof, may be administered to the patient in an amount and for a period of time which is therapeutically effective to prevent, treat, and/or manage such condition(s). These cancerous conditions include systemic and external cancers, and may also include conditions and symptoms associated with cancer. The present invention also provides a pharmaceutical composition suitable for treating such cancerous conditions. The compositions of the invention may be adapted for at least one of subcutaneous injection, intramuscular injection, intravenous injection, infusion, transdermal, or topical application.

Abstract: This invention provides for a method for treatment of corneal and dermal wounds by administering bismuth compounds in topical dosage forms. Bismuth compounds cause stimulation of release of growth factors in damaged tissue to promote regeneration of epithelial cells and hence accelerate wound healing. These bismuth compounds also have good antimicrobial activity against several anaerobic bacteria involved in diaper rash exacerbation.

Abstract: Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.

Abstract: The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.

Abstract: The invention relates to concomitant treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics in oral-topical and peroral dosage forms to eradicate H. pylori from its niches both in the dental plaque and in the gastric mucosa in order to improve the ulcer cure rate and prevent ulcer relapse. The invention also provides oral topical dosage forms with pharmaceutically usable bismuth compounds, other antibacterial compounds, and/or antibiotics that eradicate or reduce H. pylori in dental plaque. The invention further provides for treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics which are effective against Campylobacter rectus and Treponema denticola which are responsible for causing halitosis. The invention also provides bismuth compounds which have applications in wound healing, particularly in ocular and dermal wound healing.

Abstract: This invention provides for a method for treatment of corneal and dermal wounds by administering bismuth compounds in topical dosage forms. Bismuth compounds cause stimulation of release of growth factors in damaged tissue to promote regeneration of epithelial cells and hence accelerate wound healing. These bismuth compounds also have good antimicrobial activity against several anaerobic bacteria involved in diaper rash exacerbation.

Abstract: A treatment for cancer and compounds for use therewith are provided. The compounds treat cancer by correcting a TATA box lesion in DNA that leads to the cancer's uncontrolled cell proliferation. The preferred compounds each contain strontium; iodine; ascorbic acid; and a diamagnetic ion, either bismuth, zinc, or potassium. These components orient the compound, transport it to the lesion, dissociate the aberrational bonds of the lesion, hydrogenate the dissociated TATA nucleotides at the lesion, and reconvert the lesion's chemical structure to that of normal DNA.

Abstract: Antibacterial compositions comprising (1) a rifamycin derivative represented by the formula (I) or its physiologically acceptable salt, and (2) a proton pump inhibitor (a) or a bismuth preparation (b) wherein the components (1) and (2) are used in such amounts as producing a synergistic effect against Helicobacter pylori, drugs and remedies for digestive organ diseases which contain the antibacterial compositions, process for producing them, and pharmaceutical preparations related to the antibacterial compositions. The compositions can be administered to patients with digestive diseases caused by infection of Helicobacter pylori in a smaller dose and at a lower administration frequency as compared with conventional remedies.

Abstract: Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition, according to some embodiments, may further contain a pharmaceutical compound in a pharmaceutically effective amount. Non-limiting examples of pharmaceutical compounds include insulin, heparin, bismuth compounds, amantadine and rimantadine.

Abstract: Methods for controlling growth of gram negative bacteria, such as Helicobacter pylori, which are agents associated with disorders of the gastrointestinal tract of a mammal are described. They include administering a therapeutically effective amount of a polyether ionophore antibiotic to a mammal, such that growth of gram negative bacteria which are agents associated with disorders of the gastrointestinal tract of a mammal is controlled. Packaged pharmaceutical compositions for controlling gram negative bacteria are also described.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: The present invention relates to compositions and methods of induction of a cellular stress response and a protected phenotype using heavy metal ions. The invention relates to methods of protecting a mammal against injury caused by a noxious condition by administering to the mammal a heavy metal in sufficient quantity and under appropriate conditions to induce a sufficient cellular stress response to provide protection (partial or complete) against injury caused by a noxious condition. The invention also relates to methods of inducing a cellular stress response in a mammal by administering a heavy metal in sufficient quantity and under appropriate conditions to induce a cellular stress response to protect the mammal against injury caused by a noxious condition.

Abstract: The present invention relates to mucoadhesive compositions comprising a safe and effective amount of a gastrointestinal active; from about 1.5% to about 10%, by weight of the composition, of a clay component; and from about 0.01% to about 1%, by weight of the composition, of a gum component. Alternatively, the clay component can be a titanium dioxide or a silicone dioxide component. The mucoadhesive compositions also preferably comprise up to about 2% by weight of the composition, of a non-ionic component such as methyl cellulose. The present invention also relates to methods of prevention and treatment of gastrointestinal tract disorders in humans or lower animals by orally administering a composition of the present invention.

Abstract: Methods for controlling growth of gram negative bacteria, such as Helicobacter pylori, which are agents associated with disorders of the gastrointestinal tract of a mammal are described. They include administering a therapeutically effective amount of a polyether ionophore antibiotic to a mammal, such that growth of gram negative bacteria which are agents associated with disorders of the gastrointestinal tract of a mammal is controlled. Packaged pharmaceutical compositions for controlling gram negative bacteria are also described.

Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.

Abstract: The invention provides a medicament for topically treating acute bacterial infections in the oral mucosa, and methods of use. The medicament comprises a dry dosage (such as a troche or powder) of one or more antibacterial agents and, preferably, one or more polyvalent metal compounds. The medicament is directly applied to the site of the infection and dissolves in saliva, within about 5 to about 15 minutes, thereby directly delivering a supratherapeutic dosage of the antibacterial agent to the infected oral tissue. Further, in a preferred embodiment the medicament directly delivers a therapeutically high concentration of a polyvalent metal compound in suspension to the infected area, thereby forming a protective barrier over the infected oral tissue.

Abstract: Methods for administering a composition comprising bismuth and a thiol-containing complexing agent as a bacteriocidal, bacteriostatic, antifungal or antiviral agent are provided.

Abstract: The present invention provides a topical pharmaceutical composition for wound healing, which comprises (a) borneol and (b) bismuth subgallate in effective amounts. The topical pharmaceutical composition is capable of enhancing wound healing with minor irritations to injured skin, and preventing formation of scars or granulation tissues so as to help regenerate the skin with normal tenderness and appearances.

Abstract: A cosmetic composition having a lipophilic continuous phase, in particular make-up compositions, containing a novel yellow pigment of intense, saturated color, which does not generate free radicals. This novel pigment is a bismuth vanadate of formula BiVO4. By means of this pigment, it is possible to reduce the production of free radicals in the composition, when it is applied to the skin, the lips and the superficial body growths, and thus protect them. It also makes it possible to conserve the gloss of the films deposited.

Abstract: Gastrointestinal disorders involving Helicobacter pylorid are treated by administering spiramycin or spiramycin/metronidazole combinations. In addition, administration of anti-ulcer agents may be carried out before, during or after such administration of spiramycin or spiramycin/metronidazole combinations. Pharmaceutical compositions for such administrations are also disclosed.

Abstract: An asepsis disinfectant composition in liquid form having germicidal and biofilm cleansing properties comprising an anti-infective, an antiseptic agent, and an anti-biofilm agent for killing pathogenic and non-pathogenic organisms being in the range of 13.0% to 45.5% by weight of the disinfectant composition; a water purifying agent for acting as a detergent, a sanitizer and a bactericide being in the range of 4.0% to 14.0% by weight of the disinfectant composition; a cleansing agent for acting as an astringent and an abradant in the removal of biofilm from contaminated surfaces, and as a bactericide and fungicide being in the range of 10.0% to 23.0% by weight of the disinfectant composition; an anti-oxidant and stabilizer agent for stabilizing anti-infective and antiseptic agent in the liquid disinfectant composition being in the range of 4.0% to 8.

Abstract: A thermoplastic molding composition having low haze values, suitable for optical applications is disclosed. The compositions contains a resinous component selected from the group consisting of (i) a homogeneous blend of polycarbonate resin and polycaprolactone and (ii) a copoly(carbonate-lactone) block or random copolymer, and melanin in an amount of 0.1 to 1.0 parts per hundred parts of weight of the resinous component.

Abstract: A pharmaceutical, orally applicable composition is disclosed, whereby the composition contains at least one antacid active substance as well as more than 45% by weight of a sugar and/or sugar alcohol and between 12% and 35% by weight of water. The composition has a liquid or a semisolid consistency and is substantially free of preservatives.

Abstract: A composition described wherein bismuth is chelated by a complexing agent such as a pyrithione or certain other thiol compounds in the form a metal:complexing agent complex. Methods for using the composition as a bacteriocidal, bacteriostatic, antibiofilm, antifungal, and antiviral agent and as a disinfectant and preservative are also provided.

Abstract: The present invention provides antibacterial zeolite exhibiting a less discoloring action, obtained by treating the surface of zeolite supporting an antibacterial metal with 0.5 to 20% by weight, based on said zeolite, of a composition comprising (A) 100 parts by weight of a hydrolyzable silane and/or oligomer thereof which comprises 10 to 100% by weight of a hydrolyzable silane and/or oligomer thereof having an aryl group; (B) 1 to 1000 parts by weight of an organopolysiloxane having a basic nitrogen atom; and (C) 0.2 to 250 parts by weight of an acid which is soluble in water and which can form a salt with the aforesaid (B). The present antibacterial zeolite exhibits a remarkably less action of discoloring an organic polymer which contains the antibacterial zeolite when the polymer blend is placed under the influence of heat or the sunshine.

Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths.

Abstract: Methods for controlling growth of gram negative bacteria, such as Helicobacter pylori, which are agents associated with disorders of the gastrointestinal tract of a mammal are described. They include administering a therapeutically effective amount of a polyether ionophore antibiotic to a mammal, such that growth of gram negative bacteria which are agents associated with disorders of the gastrointestinal tract of a mammal is controlled. Packaged pharmaceutical compositions for controlling gram negative bacteria are also described.

Abstract: The invention provides a medicament for topically treating aphthous ulcers in the oral mucosa, and methods of use. The medicament comprises a troche or powder comprising a dry dosage of one or more antibiotics and, preferably, one or more polyvalent metal compounds. The troche or powder is directly applied to the aphthous ulcer and dissolves in saliva, within about 5 to about 15 minutes, thereby directly delivering a supratherapeutic dosage of the antibiotic to the ulcerated oral tissue. Further, in a preferred embodiment the troche/powder directly delivers a therapeutically high concentration of a polyvalent metal compound in suspension to the aphthous ulcer, thereby forming a protective barrier over the ulcerated oral tissue.

Abstract: A method for removing lice eggs from the hair of an infested human or animal using a nit-visualizing composition. The composition involves the use of certain dyes which have an affinity to the surface of nits, to thereby enable a second individual to more easily see and remove the eggs during a combing or other removal process. To effectuate this purpose, a colored material is dispersed within a water- or alcohol-based solvent and, in one embodiment, a liquefied propellant as well. The composition is applied to the hair of the infested human or animal, and then removed after drying by a process of brushing or washing. However, the colored material which adsorbs to the chitinous exoskeleton and binding cement of the lice eggs remains on the nits, thereby facilitating visual identification and removal of the lice eggs from hair.

Abstract: A composition comprising a trivalent bismuth salt, particularly bismuth nitrate, and dimercaprol is described. Methods for using the composition as a bacteriocidal and bacteriostatic agent and as a disinfectant and preservative are also provided.

Abstract: This invention relates to preservative compositions which comprise a biocidal metal compound and an fungicidal compound containing a triazole group. Methods of treating wood with the composition are also described.

Abstract: The subject invention encompasses methods for the prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa comprising administering bismuth to the subject.

Abstract: A pharmaceutical, oral composition of a liquid to semisolid consistency is disclosed, wherein the composition, substantially free of preservatives, contains at least one antacid active substance as well as more than 45% by weight, a sugar and/or sugar alcohol, relative to the ready-to-use composition, and up to 40% by weight, a pharmaceutically harmless solvent, relative to the ready-to-use composition.

Abstract: Complexes of bismuth, e.g. bismuth salts, and polyacrylate, e.g. carbomer, are discloses which may be incorporated into pharmaceutical compositions for oral, oral delayed-release, and rectal administration. The complexes may be combined with an antibiotic, such as tetracycline, and an antiprotozoal agent, e.g. Metronidazole, for use in the treatment of Helicobacter pylori infection. The treatment of inflammatory bowel disease using bismuth/polyacrylate complexes, or other bismuth preparations, is also described.

Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa.

Abstract: An object of the present invention is to provide an infusion preparation set (a container filled with infusion liquids) useful for preparation of an infusion liquid containing sugars, amino acids, electrolytes, a fat emulsion and vitamins. The present invention is constituted by the use of a container having two compartments which are separated from each other by a separation means, which contains an infusion liquid comprising a fat emulsion, sugars, fat-soluble vitamins and specified water-soluble vitamins in the first compartment and an infusion liquid comprising amino acids, electrolytes and other specified water-soluble vitamins in the second compartment. An infusion preparation containing sugars, amino acids, electrolytes, a fat emulsion and vitamins can be obtained easily and aseptically upon use, by simply removing a separation means and mixing the infusion liquids included in the first and second compartments.

Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria.

Abstract: A composition comprising a trivalent bismuth salt, particularly bismuth nitrate, and dimercaprol is described. Methods for using the composition as a bacteriocidal and bacteriostatic agent and as a disinfectant and preservative are also provided.